Advertisement
Canada markets open in 9 hours 12 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     

  • Bitcoin CAD

    87,724.39
    +184.48 (+0.21%)
     

  • CMC Crypto 200

    1,388.65
    +6.07 (+0.44%)
     

  • GOLD FUTURES

    2,346.70
    +4.20 (+0.18%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,769.50
    +202.00 (+1.15%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,909.11
    +280.63 (+0.75%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

UPDATE 1-Biohaven's ALS drug fails to meet study goals

Reuters
·1 min read

(Adds background)

Sept 29 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recent months.

The migraine drugmaker in May agreed to an $11.6 billion acquisition deal by Pfizer Inc, which plans to spin off its non-migraine drugs into a new publicly traded company.

The same month, another Biohaven drug, troriluzole, failed to meet the main goal of a late-stage study testing it in patients with a progressive nervous system disorder.

On Thursday, Biohaven said its drug for ALS did not achieve statistically significant improvement in patients' performance of daily activities compared to a placebo in a mid-to-late-stage trial.

ALS is a progressive and life-threatening neuromuscular disease, and the average age for survival is 3-5 years after the onset of first symptoms. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)